Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets.

Nearly all breast cancer deaths result from metastatic disease. Despite this, the genomic events that drive metastatic recurrence are poorly understood. We performed whole-exome and shallow whole-genome sequencing to identify genes and pathways preferentially mutated or copy-number altered in metastases compared with the paired primary tumors from which they arose. Seven genes were preferentially mutated in metastases - MYLK, PEAK1, SLC2A4RG, EVC2, XIRP2, PALB2, and ESR1 - 5 of which are not significantly mutated in any type of human primary cancer. Four regions were preferentially copy-number altered: loss of STK11 and CDKN2A/B, as well as gain of PTK6 and the membrane-bound progesterone receptor, PAQR8. PAQR8 gain was mutually exclusive with mutations in the nuclear estrogen and progesterone receptors, suggesting a role in treatment resistance. Several pathways were preferentially mutated or altered in metastases, including mTOR, CDK/RB, cAMP/PKA, WNT, HKMT, and focal adhesion. Immunohistochemical analyses revealed that metastases preferentially inactivate pRB, upregulate the mTORC1 and WNT signaling pathways, and exhibit nuclear localization of activated PKA. Our findings identify multiple therapeutic targets in metastatic recurrence that are not significantly mutated in primary cancers, implicate membrane progesterone signaling and nuclear PKA in metastatic recurrence, and provide genomic bases for the efficacy of mTORC1, CDK4/6, and PARP inhibitors in metastatic breast cancer.

[1]  M. Scaltriti,et al.  Overview of the relevance of PI3K pathway in HR-positive breast cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  G. Baillie,et al.  Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases , 2019, Proceedings of the National Academy of Sciences.

[3]  M. Esteller,et al.  A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients , 2019, Clinical Epigenetics.

[4]  C. Gerlinger,et al.  Dickkopf-1 (Dkk1) protein expression in breast cancer with special reference to bone metastases , 2018, Clinical & Experimental Metastasis.

[5]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[6]  B. Perrin,et al.  The stable actin core of mechanosensory stereocilia features continuous turnover of actin cross-linkers , 2018, Molecular biology of the cell.

[7]  A. Bellizzi,et al.  Re-Evaluating E-Cadherin and β-Catenin: A Pan-Cancer Proteomic Approach with an Emphasis on Breast Cancer. , 2018, The American journal of pathology.

[8]  Zhe Zhang,et al.  Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial , 2018, Clinical Trials.

[9]  Zhengyu Zhang,et al.  Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP‑PKA/PI3K‑Akt signaling pathway. , 2018, Molecular medicine reports.

[10]  J. Carroll,et al.  Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer , 2018, Molecular Cancer Therapeutics.

[11]  Jonathan Somma,et al.  Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells , 2018, Molecular Cancer Research.

[12]  Mads Thomassen,et al.  Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression , 2018, PloS one.

[13]  R. Schiff,et al.  PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells , 2017, npj Breast Cancer.

[14]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[15]  J. Kroep,et al.  CDK4/6 inhibition in early and metastatic breast cancer: A review. , 2017, Cancer treatment reviews.

[16]  Robert Huether,et al.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.

[17]  Nancy R. Zhang,et al.  BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers , 2017, Nature Communications.

[18]  Wei Zhou,et al.  Progesterone suppresses triple-negative breast cancer growth and metastasis to the brain via membrane progesterone receptor α , 2017, International journal of molecular medicine.

[19]  P. Lønning,et al.  Genomic Evolution of Breast Cancer Metastasis and Relapse , 2017, Cancer cell.

[20]  Robert J. Lonigro,et al.  Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.

[21]  Matt R. Paul,et al.  Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer , 2017, Breast Cancer Research and Treatment.

[22]  Daniele Naviglio,et al.  The Natural cAMP Elevating Compound Forskolin in Cancer Therapy: Is It Time? , 2017, Journal of cellular physiology.

[23]  E. Petricoin,et al.  Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer , 2017, Clinical Cancer Research.

[24]  Lajos Pusztai,et al.  Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations , 2017, Nature Communications.

[25]  Ching‐Jen Wang,et al.  The mTOR-FAK mechanotransduction signaling axis for focal adhesion maturation and cell proliferation. , 2017, American journal of translational research.

[26]  A. Viale,et al.  Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases , 2017, Clinical Cancer Research.

[27]  S. Chandarlapaty,et al.  Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. , 2017, Cancer discovery.

[28]  C. Lefebvre,et al.  Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis , 2016, PLoS medicine.

[29]  V. Lefebvre,et al.  Elevated Fibroblast Growth Factor Signaling Is Critical for the Pathogenesis of the Dwarfism in Evc2/Limbin Mutant Mice , 2016, PLoS genetics.

[30]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[31]  S. Chandarlapaty,et al.  Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence , 2016, Oncogene.

[32]  M. Boutros,et al.  Wnt signaling in cancer , 2016, Oncogene.

[33]  H. Irie,et al.  PTK6 Inhibition Suppresses Metastases of Triple-Negative Breast Cancer via SNAIL-Dependent E-Cadherin Regulation. , 2016, Cancer research.

[34]  E. Winer,et al.  PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers , 2016, Oncogene.

[35]  F. Bertucci,et al.  Comparative genomic analysis of primary tumors and metastases in breast cancer , 2016, Oncotarget.

[36]  R. Weinberg,et al.  Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability , 2016, Science.

[37]  T. Beißbarth,et al.  β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases , 2016, Clinical & Experimental Metastasis.

[38]  Ahmedin Jemal,et al.  Global Cancer Incidence and Mortality Rates and Trends—An Update , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[39]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[40]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[41]  R. Klemke,et al.  PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer , 2015, PloS one.

[42]  Webster K. Cavenee,et al.  Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance , 2015, Proceedings of the National Academy of Sciences.

[43]  J. Steinbach,et al.  Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors , 2015, PloS one.

[44]  M. Royce,et al.  Everolimus in the Treatment of Metastatic Breast Cancer , 2015, Breast cancer : basic and clinical research.

[45]  Pieter Wesseling,et al.  DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly , 2014, Genome research.

[46]  Juan Li,et al.  Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion , 2014, Journal of experimental & clinical cancer research : CR.

[47]  Yulei N. Wang,et al.  High mobility group Box-1 inhibits cancer cell motility and metastasis by suppressing activation of transcription factor CREB and nWASP expression , 2014, Oncotarget.

[48]  A. Tutt,et al.  Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers , 2014, Breast Cancer Research.

[49]  Wenqi Jiang,et al.  The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. , 2014, International journal of oncology.

[50]  P. V. van Diest,et al.  PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy , 2014, International journal of cancer.

[51]  Michael P. Schroeder,et al.  IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.

[52]  Ker-Chau Li,et al.  Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity , 2013, BMC Medicine.

[53]  M. Jo,et al.  Dynamic Phosphorylation of Tyrosine 665 in Pseudopodium-enriched Atypical Kinase 1 (PEAK1) Is Essential for the Regulation of Cell Migration and Focal Adhesion Turnover* , 2012, The Journal of Biological Chemistry.

[54]  R. Rohatgi,et al.  A Smoothened-Evc2 complex transduces the Hedgehog signal at primary cilia. , 2012, Developmental cell.

[55]  J. Asara,et al.  Protein Tyrosine Kinase 6 Protects Cells from Anoikis by Directly Phosphorylating Focal Adhesion Kinase and Activating AKT , 2012, Oncogene.

[56]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[57]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[58]  Jason H. Yang,et al.  Regulation of Nuclear PKA revealed by spatiotemporal manipulation of cAMP , 2011, Nature chemical biology.

[59]  G. Mills,et al.  ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. , 2011, Cancer discovery.

[60]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[61]  T. Beißbarth,et al.  β-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. , 2011, Carcinogenesis.

[62]  Giovanni Parmigiani,et al.  Patient-oriented gene set analysis for cancer mutation data , 2010, Genome Biology.

[63]  A. Tyner,et al.  Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. , 2010, Biochimica et biophysica acta.

[64]  R. Shaw,et al.  The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.

[65]  G. Peters,et al.  Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma‐prone families or patients , 2009, Human mutation.

[66]  A. Olson,et al.  GLUT4 Enhancer Factor (GEF) Interacts with MEF2A and HDAC5 to Regulate the GLUT4 Promoter in Adipocytes* , 2008, Journal of Biological Chemistry.

[67]  H. Randeva,et al.  Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. , 2006, Molecular endocrinology.

[68]  F. Couch,et al.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. , 2006, Molecular cell.

[69]  I. Bossis,et al.  Minireview: PRKAR1A: normal and abnormal functions. , 2004, Endocrinology.

[70]  Klemens Rottner,et al.  Xin repeats define a novel actin-binding motif , 2004, Journal of Cell Science.

[71]  R. Nusse,et al.  The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.

[72]  A. Floore,et al.  Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. , 2004, Cancer cell.

[73]  Donna J. Webb,et al.  FAK–Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly , 2004, Nature Cell Biology.

[74]  A. Harvey,et al.  Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation , 2003, Oncogene.

[75]  John D. Scott,et al.  A-kinase anchoring proteins and neuronal signaling mechanisms. , 2003, Genes & development.

[76]  Robert D Cardiff,et al.  Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. , 2003, Genes & development.

[77]  P. Stork,et al.  Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. , 2002, Trends in cell biology.

[78]  Weng-Lang Yang,et al.  Reinventing the Wheel of Cyclic AMP , 2002 .

[79]  A. Lindblom,et al.  Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p , 2000, Clinical genetics.

[80]  A. Børresen-Dale,et al.  Re‐expression of E‐cadherin, α‐catenin and β‐catenin, but not of γ‐catenin, in metastatic tissue from breast cancer patients , 2000 .

[81]  J. Guan,et al.  Regulation of the Cell Cycle by Focal Adhesion Kinase , 1998, The Journal of cell biology.

[82]  E. Wieschaus,et al.  The vertebrate adhesive junction proteins beta-catenin and plakoglobin and the Drosophila segment polarity gene armadillo form a multigene family with similar properties , 1992, The Journal of cell biology.

[83]  Matt R. Paul,et al.  Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer , 2017, Breast Cancer Research and Treatment.

[84]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[85]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[86]  O. Olopade,et al.  Stem Cells , Tissue Engineering and Hematopoietic Elements Wnt /-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome , 2010 .

[87]  Weng-Lang Yang,et al.  Reinventing the wheel of cyclic AMP: novel mechanisms of cAMP signaling. , 2002, Annals of the New York Academy of Sciences.

[88]  A. Børresen-Dale,et al.  Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]. , 2000, The Journal of pathology.